• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
1030949

血友病治療的全球市場:各類型、各產品、各治療法、各治療藥物、各地區的競爭預測與市場機會 (2026年)

Global Haemophilia Treatment Market, By Type, By Product, By Treatment, By Therapy, By Region, Competition Forecast & Opportunities, 2026
出版日期: | 出版商: TechSci Research | 英文 119 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

  • 全貌
  • 簡介
  • 目錄
簡介

全球血友病治療的市場規模，2020年為139億645美金，在預測期間內預計以9.06％的年複合成長率成長，2026年達到242億539萬美元。

市場主要促進因素，是血友病相關啟發活動的活躍，對新治療方法開發的持續性研究開發 (R&D) 活動，出血性疾病的發病率劇增等。

在各類型中，A型血友病產品佔大半，今後也預計將持續此趨勢。在各地區中，北美各國是最大的市場，以及亞太地區各國也預計有高成長率。

本報告提供全球血友病治療的市場相關分析，整體市場規模趨勢預測和市場佔有率結構 (各類型、各產品、各治療法、各治療藥物)，各地區、主要國家詳細趨勢，主要的推動及阻礙市場要素，企業間的市場競爭結構，主要企業的簡介，今後的市場成長的方向性等調查。

目錄

第1章 產品概要

第2章 分析方法

第3章 COVID-19對全球血友病治療市場的影響

第4章 摘要整理

第5章 客戶方面的見解

  • 品牌認知度
  • 未滿足需求與課題
  • 藥物購買的影響因素

第6章 全球血友病治療市場:未來展望

  • 市場規模與其預測
    • 以金額為準
  • 市場佔有率與其預測
    • 各類型 (A型血友病，B型血友病，血友病C)
    • 各產品 (重組凝固凝血因子濃縮劑，血漿來源凝固凝血因子濃縮劑，去氨加壓素，抗線溶藥)
    • 各治療法 (隨選 (出血時補充療法)，預防治療)
    • 各治療藥物 (補充療法，免疫寬恕引進療法 (ITI)，基因治療)
    • 各企業 (2020年)
    • 各地區
  • 產品市場地圖

第7章 北美的血友病治療市場:未來展望

  • 市場規模與其預測
  • 市場佔有率與其預測
  • 北美:各國分析
    • 美國市場
    • 加拿大市場
    • 墨西哥市場

第8章 歐洲的血友病治療市場:未來展望

  • 市場規模與其預測
  • 市場佔有率與其預測
  • 歐洲:各國分析
    • 德國市場
    • 英國市場
    • 法國市場
    • 義大利市場
    • 西班牙市場

第9章 亞太地區的血友病治療市場:未來展望

  • 市場規模與其預測
  • 市場佔有率與其預測
  • 亞太地區:各國分析
    • 印度市場
    • 中國市場
    • 日本市場
    • 澳洲市場
    • 韓國市場

第10章 南美的血友病治療市場:未來展望

  • 市場規模與其預測
  • 市場佔有率與其預測
  • 南美:各國分析
    • 巴西市場
    • 阿根廷市場
    • 哥倫比亞市場

第11章 中東、非洲的血友病治療市場:未來展望

  • 市場規模與其預測
  • 市場佔有率與其預測
  • 中東、非洲:各國分析
    • 沙烏地阿拉伯市場
    • 阿拉伯聯合大公國市場
    • 南非市場

第12章 市場動態

  • 促進因素
  • 課題

第13章 市場趨勢和動靜

第14章 競爭情形

  • Novo Nordisk A/S
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company
  • Sanofi S.A.
  • CSL Behring LLC
  • BioMarin Pharmaceutical Inc.
  • Octapharma AG
  • Sangamo Therapeutics Inc.
  • Eagle Pharmaceuticals Inc.
  • Baxter International, Inc.
  • Grifols SA
  • Biogen Idec, Inc.
  • Alnylam Pharmaceuticals Inc.

第15章 策略建議

第16章 TechSci Research相關資料，免責聲明

目錄
Product Code: 5057

Global haemophilia treatment market was valued at USD13906.45 million in 2020 and is forecast to reach USD24205.39 million in 2026 by registering a CAGR of 9.06% during the forecast period. The global haemophilia treatment market is driven by increasing awareness campaigns regarding haemophilia among the population across the globe. Moreover, ongoing attempts in research and development activities for the development of new therapy solutions is positively impacting the growth of the market. Also, surging incidences of bleeding disorders have been observed worldwide, which is further expected to bolster the growth of market over the next few years.

The global haemophilia treatment market is segmented based on type, product, treatment, therapy, company and region. Based on type, the market can be categorized into Haemophilia A, Haemophilia B and Haemophilia C. Generally, the classification depends on the deficiency of coagulation factor present in a patient. Based on that, type A is the most frequent type, and the prevalence rate has been recorded to be four times more than haemophilia type B. In addition to this, majority of existing products are used for treating type A haemophilia, which is contributing to the increasing growth of the segment over the coming years.

Regionally, the market is segregated into North America, Europe, Asia- Pacific, South America and Middle East and Africa. Out of which, North America dominated the global haemophilia treatment market in 2020 owing to increased prevalence of haemophilia A & B in the United States and Canada. Besides this, organic and inorganic strategies of major pharmaceutical companies present in the United States is further contributing to the market growth in the region. Additionally, Asia Pacific region is expected to grow at the fastest rate in the coming years. This high growth can be ascribed to the ease of regulatory policies in Australia and Japan for the approval of drugs for the treatment of haemophilia A. In addition to this, improved funding by public and private players for the improvisation of healthcare facilities in India and China, is further anticipated the drive the market growth in Asia Pacific.

Major players operating in the global haemophilia treatment market include Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Company, Sanofi S.A., CSL Behring LLC, BioMarin Pharmaceutical Inc., Octapharma AG, Sangamo Therapeutics Inc., Eagle Pharmaceuticals Inc., Baxter International, Inc., Grifols SA, Biogen Idec, Inc., Alnylam Pharmaceuticals Inc., and others. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, therefore helping the industry to solve existing challenges and meet the unmet needs in the market. Besides, these major market players are focusing on new product development, mergers and acquisitions, and business expansion to attain a higher market share.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022-2026

Objective of the Study:

  • To analyze the historical growth in the market size of global haemophilia treatment market from 2016 to 2020.
  • To estimate and forecast the market size of global haemophilia treatment market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global haemophilia treatment market based on type, product, treatment, therapy, company and regional distribution.
  • To identify dominant region or segment in the global haemophilia treatment market.
  • To identify drivers and challenges for global haemophilia treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global haemophilia treatment market.
  • To conduct pricing analysis for global haemophilia treatment market.
  • To identify and analyze the profile of leading players operating in global haemophilia treatment market.
  • To identify key sustainable strategies adopted by market players in global haemophilia treatment market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/labs and presence of all major players across the globe.

TechSci Research calculated the market size of global haemophilia treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Haemophilia treatment facilities, companies and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to haemophilia treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global haemophilia treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Haemophilia Treatment Market, By Type:

Haemophilia A

Haemophilia B

Haemophilia C

  • Global Haemophilia Treatment Market, By Product:

Recombinant Coagulation Factor Concentrates

Plasma Derived Coagulation Factor Concentrate

Desmopressin

Antifibrinolytics Agents

  • Global Haemophilia Treatment Market, By Treatment:

On-demand

Prophylaxis

  • Global Haemophilia Treatment Market, By End-user:

Replacement Therapy

ITI therapy

Gene Therapy

  • Global Haemophilia Treatment Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain

Asia-Pacific

  • India
  • China
  • Japan
  • Australia
  • South Korea

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • Saudi Arabia
  • UAE
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global haemophilia treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Haemophilia Treatment Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Brand Awareness
  • 5.2. Unmet Needs & Challenges
  • 5.3. Factors Influencing Drug Purchase

6. Global Haemophilia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Haemophilia A, Haemophilia B, Haemophilia C)
    • 6.2.2. By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents)
    • 6.2.3. By Treatment (On-demand and Prophylaxis)
    • 6.2.4. By Therapy (Replacement Therapy, ITI Therapy and Gene Therapy)
    • 6.2.5. By Company (2020)
    • 6.2.6. By Region
  • 6.3. Product Market Map

7. North America Haemophilia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Treatment
    • 7.2.4. By Therapy
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Haemophilia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Treatment
        • 7.3.1.2.4. By Therapy
    • 7.3.2. Canada Haemophilia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Treatment
        • 7.3.2.2.4. By Therapy
    • 7.3.3. Mexico Haemophilia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Treatment
        • 7.3.3.2.4. By Therapy

8. Europe Haemophilia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Treatment
    • 8.2.4. By Therapy
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Haemophilia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Treatment
        • 8.3.1.2.4. By Therapy
    • 8.3.2. United Kingdom Haemophilia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Treatment
        • 8.3.2.2.4. By Therapy
    • 8.3.3. France Haemophilia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Treatment
        • 8.3.3.2.4. By Therapy
    • 8.3.4. Italy Haemophilia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Treatment
        • 8.3.4.2.4. By Therapy
    • 8.3.5. Spain Haemophilia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Treatment
        • 8.3.5.2.4. By Therapy

9. Asia-Pacific Haemophilia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Treatment
    • 9.2.4. By Therapy
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. India Haemophilia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Treatment
        • 9.3.1.2.4. By Therapy
    • 9.3.2. China Haemophilia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Treatment
        • 9.3.2.2.4. By Therapy
    • 9.3.3. Japan Haemophilia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Treatment
        • 9.3.3.2.4. By Therapy
    • 9.3.4. Australia Haemophilia Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Product
        • 9.3.4.2.3. By Treatment
        • 9.3.4.2.4. By Therapy
    • 9.3.5. South Korea Haemophilia Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Product
        • 9.3.5.2.3. By Treatment
        • 9.3.5.2.4. By Therapy

10. South America Haemophilia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Treatment
    • 10.2.4. By Therapy
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Haemophilia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Treatment
        • 10.3.1.2.4. By Therapy
    • 10.3.2. Argentina Haemophilia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Treatment
        • 10.3.2.2.4. By Therapy
    • 10.3.3. Colombia Haemophilia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Treatment
        • 10.3.3.2.4. By Therapy

11. Middle East and Africa Haemophilia Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Product
    • 11.2.3. By Treatment
    • 11.2.4. By Therapy
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. Saudi Arabia Haemophilia Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Product
        • 11.3.1.2.3. By Treatment
        • 11.3.1.2.4. By Therapy
    • 11.3.2. UAE Haemophilia Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Product
        • 11.3.2.2.3. By Treatment
        • 11.3.2.2.4. By Therapy
    • 11.3.3. South Africa Haemophilia Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Product
        • 11.3.3.2.3. By Treatment
        • 11.3.3.2.4. By Therapy

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Novo Nordisk A/S
  • 14.2. F. Hoffmann-La Roche AG
  • 14.3. Bayer AG
  • 14.4. Pfizer, Inc.
  • 14.5. Takeda Pharmaceutical Company
  • 14.6. Sanofi S.A.
  • 14.7. CSL Behring LLC
  • 14.8. BioMarin Pharmaceutical Inc.
  • 14.9. Octapharma AG
  • 14.10. Sangamo Therapeutics Inc.
  • 14.11. Eagle Pharmaceuticals Inc.
  • 14.12. Baxter International, Inc.
  • 14.13. Grifols SA
  • 14.14. Biogen Idec, Inc.
  • 14.15. Alnylam Pharmaceuticals Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Figures

  • Figure 1: Global Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 2: Global Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 3: Global Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 4: Global Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 5: Global Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 6: Global Haemophilia Treatment Market Share, By Company, 2020
  • Figure 7: Global Haemophilia Treatment Market Share, By Region, By Value, 2016-2026F
  • Figure 8: Global Haemophilia Treatment Product Market Map, By Value, 2016-2026F
  • Figure 9: North America Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 10: North America Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 11: North America Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 12: North America Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 13: North America Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 14: North America Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F
  • Figure 15: United States Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 16: United States Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 17: United States Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 18: United States Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 19: United States Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 20: Canada Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 21: Canada Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 22: Canada Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 23: Canada Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 24: Canada Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 25: Mexico Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 26: Mexico Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 27: Mexico Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 28: Mexico Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 29: Mexico Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 30: Europe Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 31: Europe Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 32: Europe Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 33: Europe Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 34: Europe Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 35: Europe Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F
  • Figure 36: Germany Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 37: Germany Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 38: Germany Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 39: Germany Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 40: Germany Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 41: United Kingdom Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 42: United Kingdom Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 43: United Kingdom Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 44: United Kingdom Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 45: United Kingdom Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 46: France Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 47: France Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 48: France Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 49: France Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 50: France Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 51: Italy Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 52: Italy Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 53: Italy Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 54: Italy Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 55: Italy Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 56: Spain Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 57: Spain Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 58: Spain Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 59: Spain Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 60: Spain Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 61: Asia Pacific Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 62: Asia Pacific Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 63: Asia Pacific Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 64: Asia Pacific Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 65: Asia Pacific Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 66: Asia Pacific Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F
  • Figure 67: India Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 68: India Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 69: India Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 70: India Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 71: India Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 72: China Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 73: China Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 74: China Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 75: China Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 76: China Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 77: Japan Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 78: Japan Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 79: Japan Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 80: Japan Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 81: Japan Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 82: Australia Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 83: Australia Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 84: Australia Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 85: Australia Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 86: Australia Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 87: South Korea Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 88: South Korea Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 89: South Korea Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 90: South Korea Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 91: South Korea Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 92: South America Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 93: South America Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 94: South America Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 95: South America Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 96: South America Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F
  • Figure 97: Brazil Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 98: Brazil Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 99: Brazil Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 100: Brazil Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 101: Brazil Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 102: Argentina Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 103: Argentina Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 104: Argentina Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 105: Argentina Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 106: Argentina Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 107: Colombia Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 108: Colombia Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 109: Colombia Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 110: Colombia Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 111: Colombia Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 112: Middle East & Africa Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 113: Middle East & Africa Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 114: Middle East & Africa Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 115: Middle East & Africa Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 116: Middle East & Africa Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 117: Middle East & Africa Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F
  • Figure 118: Saudi Arabia Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 119: Saudi Arabia Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 120: Saudi Arabia Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 121: Saudi Arabia Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 122: Saudi Arabia Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 123: UAE Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 124: UAE Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 125: UAE Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 126: UAE Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 127: UAE Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F
  • Figure 128: South Africa Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
  • Figure 129: South Africa Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F
  • Figure 130: South Africa Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F
  • Figure 131: South Africa Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F
  • Figure 132: South Africa Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F